Results 61 to 70 of about 1,821 (152)

Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment: Nanoparticles Delivery Systems Approach. [PDF]

Pharmaceutics
Herdiana Y, Wardhana YW, Kurniawansyah IS, Gozali D, Wathoni N, Sofian FF.   +5 more
europepmc   +1 more source

Integrating Renal and Metabolic Parameters into a Derived Risk Score for Hyperuricemia in Uncontrolled Type 2 Diabetes: A Retrospective Cross-Sectional Study in Northwest Romania. [PDF]

Medicina (Kaunas)
Paduraru L, Zaha DC, Ghitea TC, Fodor R, Vesa CM, Popoviciu MS.   +5 more
europepmc   +1 more source

The era of combination of nephroprotective agents in CKD is there. [PDF]

Nephrol Dial Transplant
Jadoul M, Rossing P.
europepmc   +1 more source

<i>Monascus</i> Yellow Pigments Ameliorate Hyperuricemia via Dual Mechanisms: Xanthine Oxidase Inhibition and Uric Acid Transporter Modulation (ABCG2, URAT1, and GLUT9). [PDF]

Foods
Xue F, Zhu R, Li J, Liu Z, Niu L, Chen W, Wang C, Zheng J.   +7 more
europepmc   +1 more source

Molecular mechanism of drug inhibition of URAT1. [PDF]

Nat Commun
Yu Z, Hu T, Su J, Zhao J, Li R, Ma Q, Chen Q, Bai Q, Dong Y, Yuan P, Li N, Zhang XC, Zhao Y.   +12 more
europepmc   +1 more source

New Insights into Uric Acid Metabolism in the Pathophysiology of Ischaemic Heart Disease. [PDF]

Eur Cardiol
Piani F, Annesi L, Borghi C.
europepmc   +1 more source

Gout management: Patent analytics and computational drug design explores URAT1 inhibitors landscape. [PDF]

PLoS One
Zhang J, Hong L, Xu W, Zhang X, Fu H, Song X, Zhao J.   +6 more
europepmc   +1 more source

Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia. [PDF]

Sci Rep
Takata T, Taniguchi S, Mae Y, Kageyama K, Fujino Y, Iyama T, Hikita K, Sugihara T, Isomoto H.   +8 more
europepmc   +1 more source

Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management. [PDF]

Int J Mol Sci
Riccioni G, Notarangelo C, Riccioni M, D'Orazio N.   +3 more
europepmc   +1 more source